Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 05:00PM GMT
Release Date Price: €25.88 (+3.40%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

Okay. I think we're ready. So good morning, everybody. Thanks for joining us here at the Bank of America Conference in Las Vegas. I'm Tazeen Ahmad. I'm one of the senior SMid biotech analyst here. It's my pleasure to have our next presenting company with me, Denali Therapeutics. Presenting for Denali is CEO, Ryan Watts. So good morning, Ryan.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Yes. Great to be here. Thank you.

Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst

So for those who might not be as familiar with the company, maybe just give us a 2-minute overview. There's a lot going on, obviously, but maybe just the top level stuff, and we can go straight into Q&A after that.

Ryan J. Watts
Denali Therapeutics Inc. - Co-Founder, President, CEO & Director

Yes. Great. So definitely a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot